[D] Aspira Women's Health Inc. SEC Filing

Rhea-AI Filing Summary

Aspira Women's Health Inc. filed a Form D reporting a Regulation D offering under Rule 506(b). The company stated a $2,950,000 total offering size and reports $2,950,000 sold with $0 remaining, indicating the offering has been fully sold. The first sale date is listed as 2025-09-16. The securities offered include equity, options/warrants or other rights to acquire securities, and the securities issuable upon exercise of those rights. The filing lists 19 investors to date, indicates the offering will not last more than one year, and shows $0 in sales commissions and finders' fees. The company disclosed $0 of proceeds paid to named executive officers, directors or promoters. The Form D was signed by Michael Buhle, Chief Executive Officer, on 2025-09-18.

Positive

• Offering fully sold: Total offering amount of $2,950,000 equals total amount sold of $2,950,000 with $0 remaining.
• No sales commissions or finders' fees: Sales commissions reported as $0 and finders' fees reported as $0.
• No proceeds to named insiders: Use of proceeds discloses $0 to executive officers, directors or promoters.
• Clear regulatory exemption: Offering claimed under Rule 506(b) of Regulation D.

Negative

• None.

Insights

Securities Capital Markets Analyst

TL;DR: A small Reg D equity offering under Rule 506(b) was fully sold for $2.95M with no commissions and no proceeds paid to insiders.

The filing documents a completed private placement under Rule 506(b) raising $2,950,000, with the same amount reported as sold and zero remaining. That suggests the issuer secured the targeted amount without paying third-party sales compensation, which reduces cash outflows related to distribution. Use-of-proceeds disclosure shows no direct payments to named insiders, which is relevant for governance and related-party scrutiny. The offering included equity and options/warrants, and 19 investors are listed as participants. The first sale date noted is 2025-09-16 and the filing was signed on 2025-09-18.

Corporate Governance Specialist

TL;DR: Documentation reflects a routine private offering with clear signer certification and no disclosed insider payments.

The Form D supplies standard regulatory disclosures: issuer identity, offering exemption (Rule 506(b)), investor count, states of solicitation, and signature certification by the CEO. The explicit statement of $0 paid to executive officers, directors or promoters is a noteworthy governance disclosure. Absence of sales commissions and finders' fees simplifies post-offering reconciliation and reduces potential conflicts over placement agents. The filing is a standard, materially neutral disclosure for investors and regulators.

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM D

Notice of Exempt Offering of Securities

OMB APPROVAL

OMB Number:			3235-0076
Estimated average burden
hours per response:			4.00

1. Issuer's Identity

CIK (Filer ID Number)

Previous Names

None

Entity Type

0000926617

VERMILLION, INC.

CIPHERGEN BIOSYSTEMS INC

ABIOTIC SYSTEMS

CIPHERGEN BIOSYSTEMS INC.

X	Corporation
	Limited Partnership
	Limited Liability Company
	General Partnership
	Business Trust
	Other (Specify)

Name of Issuer

Aspira Women's Health Inc.

Jurisdiction of Incorporation/Organization

DELAWARE

Year of Incorporation/Organization

X	Over Five Years Ago
	Within Last Five Years (Specify Year)
	Yet to Be Formed

2. Principal Place of Business and Contact Information

Name of Issuer
Aspira Women's Health Inc.
Street Address 1		Street Address 2
12117 BEE CAVES ROAD		BUILDING III, SUITE 100
City	State/Province/Country	ZIP/PostalCode	Phone Number of Issuer
AUSTIN	TEXAS	78738	(512) 519-0400

3. Related Persons

Last Name	First Name	Middle Name
BUHLE	MICHAEL
Street Address 1	Street Address 2
12117 BEE CAVES ROAD	BUILDING III, SUITE 100
City	State/Province/Country	ZIP/PostalCode
AUSTIN	TEXAS	78738

Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):

Chief Executive Officer

Last Name	First Name	Middle Name
HUNGERFORD	BRIAN
Street Address 1	Street Address 2
12117 BEE CAVES ROAD	BUILDING III, SUITE 100
City	State/Province/Country	ZIP/PostalCode
AUSTIN	TEXAS	78738

Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):

Chief Financial Officer

Last Name	First Name	Middle Name
FRASER	JACK
Street Address 1	Street Address 2
12117 BEE CAVES ROAD	BUILDING III, SUITE 100
City	State/Province/Country	ZIP/PostalCode
AUSTIN	TEXAS	78738

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
COHEN	JEFFREY
Street Address 1	Street Address 2
12117 BEE CAVES ROAD	BUILDING III, SUITE 100
City	State/Province/Country	ZIP/PostalCode
AUSTIN	TEXAS	78738

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
WOOD	Jane	PINE
Street Address 1	Street Address 2
12117 BEE CAVES ROAD	BUILDING III, SUITE 100
City	State/Province/Country	ZIP/PostalCode
AUSTIN	TEXAS	78738

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
BEAUSANG	ELLEN
Street Address 1	Street Address 2
12117 BEE CAVES ROAD	BUILDING III, SUITE 100
City	State/Province/Country	ZIP/PostalCode
AUSTIN	TEXAS	78738

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
HUNDORFEAN	CYNTHIA
Street Address 1	Street Address 2
12117 BEE CAVES ROAD	BUILDING III, SUITE 100
City	State/Province/Country	ZIP/PostalCode
AUSTIN	TEXAS	78738

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
PARNELL	WINFRED
Street Address 1	Street Address 2
12117 BEE CAVES ROAD	BUILDING III, SUITE 100
City	State/Province/Country	ZIP/PostalCode
AUSTIN	TEXAS	78738

Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

4. Industry Group

Agriculture

Banking & Financial Services

Commercial Banking

Insurance

Investing

Investment Banking

Pooled Investment Fund

Is the issuer registered as
an investment company under
the Investment Company
Act of 1940?

Yes No

Other Banking & Financial Services

Business Services

Energy

Coal Mining

Electric Utilities

Energy Conservation

Environmental Services

Oil & Gas

Other Energy

	Health Care
	X Biotechnology
	Health Insurance
	Hospitals & Physicians
	Pharmaceuticals
	Other Health Care
	Manufacturing
	Real Estate
	Commercial
	Construction
	REITS & Finance
	Residential
	Other Real Estate

Retailing

Restaurants

Technology

Computers

Telecommunications

Other Technology

Travel

Airlines & Airports

Lodging & Conventions

Tourism & Travel Services

Other Travel

Other

5. Issuer Size

Revenue Range		OR	Aggregate Net Asset Value Range
	No Revenues			No Aggregate Net Asset Value
	$1 - $1,000,000			$1 - $5,000,000
	$1,000,001 - $5,000,000			$5,000,001 - $25,000,000
	$5,000,001 - $25,000,000			$25,000,001 - $50,000,000
	$25,000,001 - $100,000,000			$50,000,001 - $100,000,000
	Over $100,000,000			Over $100,000,000
X	Decline to Disclose			Decline to Disclose
	Not Applicable			Not Applicable

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

		Rule 504(b)(1) (not (i), (ii) or (iii))
		Rule 504 (b)(1)(i)
		Rule 504 (b)(1)(ii)
		Rule 504 (b)(1)(iii)
	X	Rule 506(b)
		Rule 506(c)
		Securities Act Section 4(a)(5)

Investment Company Act Section 3(c)

Section 3(c)(1) Section 3(c)(9)

Section 3(c)(2) Section 3(c)(10)

Section 3(c)(3) Section 3(c)(11)

Section 3(c)(4) Section 3(c)(12)

Section 3(c)(5) Section 3(c)(13)

Section 3(c)(6) Section 3(c)(14)

Section 3(c)(7)

7. Type of Filing

X	New Notice			Date of First Sale	2025-09-16				First Sale Yet to Occur
	Amendment

8. Duration of Offering

Does the Issuer intend this offering to last more than one year? Yes X No

9. Type(s) of Securities Offered (select all that apply)

X	Equity		Pooled Investment Fund Interests
	Debt		Tenant-in-Common Securities
X	Option, Warrant or Other Right to Acquire Another Security		Mineral Property Securities
X	Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security		Other (describe)

10. Business Combination Transaction

Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? Yes X No

Clarification of Response (if Necessary):

11. Minimum Investment

Minimum investment accepted from any outside investor $0 USD

12. Sales Compensation

Recipient	Recipient CRD Number X None
None	None
(Associated) Broker or Dealer X None	(Associated) Broker or Dealer CRD Number X None
None	None
Street Address 1	Street Address 2
None	None
City	State/Province/Country	ZIP/Postal Code
None	Unknown	None
State(s) of Solicitation (select all that apply) Check "All States" or check individual States All States	Foreign/non-US
CALIFORNIA FLORIDA ILLINOIS LOUISIANA NEW YORK PENNSYLVANIA VIRGINIA WISCONSIN

13. Offering and Sales Amounts

Total Offering Amount	$2,950,000	USD	or Indefinite
Total Amount Sold	$2,950,000	USD
Total Remaining to be Sold	$0	USD	or Indefinite

Clarification of Response (if Necessary):

14. Investors

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.

Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:

19

15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions	$0	USD	Estimate
Finders' Fees	$0	USD	Estimate

Clarification of Response (if Necessary):

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

$0

USD

Estimate

Clarification of Response (if Necessary):

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

• Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*

• Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.

• Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Aspira Women's Health Inc.	/s/ Michael Buhle	Michael Buhle	Chief Executive Officer	2025-09-18

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.

FAQ

What exemption did Aspira Women's Health Inc. (AWHL) claim for this offering?

The company claimed an exemption under Rule 506(b) of Regulation D.

How much capital did Aspira raise in this Form D filing?

The total offering amount is $2,950,000, and the filing reports $2,950,000 sold with $0 remaining.

When was the first sale reported for the offering?

The filing lists the date of first sale as 2025-09-16.

How many investors participated in the offering?

The Form D reports a total of 19 investors who already invested.

Were any sales commissions or finders' fees paid?

No; the filing reports $0 for sales commissions and $0 for finders' fees.

Did the company disclose payments to executives or directors from the offering proceeds?

The Form D discloses $0 of the gross proceeds used for payments to named executive officers, directors or promoters.